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Comparative output reviews 
Some international benchmarks for evaluating 
Australian health and medical research 
Sam Garrett-Jones, Brian Wixted and Tim Turpin
Recent experience in Australia has seen the re-
quirement by the federal Department of Finance 
and Administration to conduct output pricing 
reviews of government agencies including re-
search organisations. Health and medical re-
search, while generally regarded as an important 
‘public good’, is now pressed by the same de-
mands as other research fields to account for 
public investments in terms of value of outcomes 
and value for investment. This paper reports on 
current trends towards international benchmark-
ing of health and medical research performance. 
Comparative data from overseas show unique 
aspects of the Australian health and medical re-
search funding system. The paper suggests pos-
sible future routes for carrying out health 
research evaluation in Australia. 
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This is an extended version of a paper presented at the confer-
ence on Health Outcomes 2003: The Quest for Practice Im-
provement, 9th Annual National Conference, Canberra, 
Australia, 20–21 August 2003. 
OVERNMENTS AROUND THE WORLD 
are demanding greater accountability and 
efficiency in the use of public monies for 
research. This pressure to demonstrate outcomes and 
effective use of funds has extended to research insti-
tutes and research councils. The health and medical 
research and development (HMRD) community has 
perhaps been more insulated than have, say, re-
searchers in the social sciences. Governments appear 
to have accepted incontestably that HMRD is a pub-
lic good that is carried out to the highest professional 
standards. There has been strong community support 
for HMRD, and last but not least the medical estab-
lishment and researchers are very effective lobbyists. 
Even so, HMRD is now operating in an environment 
of greater public accountability which is affecting all 
government-run or government-funded bodies. 
Demand for research performance evaluation 
Through the 1990s there was growing pressure on 
research funding agencies in most countries to report 
on the return to society of publicly funded national 
research investments and on the specific ‘results’ or 
outcomes of that investment. In several countries, 
this requirement has become enshrined in legislation 
or administrative regulation. In the United States, the 
1993 Government Performance and Results Act 
(GPRA) requires strategic planning and performance 
reporting for all government activities, including 
research (Cozzens, 2000). Agencies such as the Na-
tional Institutes of Health (NIH), which support fun-
damental research, now produce annual performance 
plans that assess the institutes’ achievement of its 
performance targets. Most of NIH’s performance 
G
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goals are expressed objectively or quantitatively; 
other goals are assessed through an ‘alternative 
form’ such as descriptive criteria (Ordóñez-
Matamoros, 2003). 
In Australia, federal government research agen-
cies including the National Health and Medical Re-
search Council (NHMRC) and CSIRO have since 
1999 been subject to output pricing reviews by the 
Department of Finance and Administration (DoFA). 
These reviews examine the quantity, quality and 
price of outputs produced in an attempt to assess 
whether the government is getting good value for the 
taxpayers’ funds. The process emphasises indicators 
of agency outputs and outcomes. 
•  Outcomes in this context refer to longer-term im-
pact or effect expected or intended in a particular 
policy arena. 
•  Outputs are the immediate ‘deliverables’ — the 
goods and services — produced by the agency 
(Department of Finance and Administration, 
2000). 
As one moves from outputs to impacts, the results of 
research activity are generally broader in their effect, 
take longer to manifest themselves, are harder to 
quantify and are less readily traceable to particular 
research projects, funding programs or agencies. 
This is the so-called ‘attribution factor’. While de-
sired impacts may be seen, they have a plurality of 
causes, the individual contribution of which is not 
readily measurable. For example, while it may be 
possible to demonstrate statistically a decline in 
mortality or morbidity from a particular disease, it is 
in most circumstances impossible to attribute this 
with any confidence to a single cause, such as a  
major NHMRC research program on the topic. 
There is an inherent difficulty too, as US researcher 
Paul David notes in respect of NIH, in requiring re-
search agencies to consider ‘outcomes beyond the 
span of control of the agencies which are being 
asked to define their outcomes’ (Feller, 2002). 
The Australian federal government framework 
therefore sensibly recognises that research agencies 
are valued as much for their standing capacity to 
deliver research expertise as for their specific R&D 
activities. In practice, the output pricing reviews of 
research agencies have been largely qualitative in 
nature (Commonwealth Scientific and Industrial Re-
search Organisation, 2002). 
International performance indicators 
In the case of Australian HMRD, the results of per-
formance evaluation have usually been used to jus-
tify greater investment and targeting of that 
investment. As the primary funding body, the 
NHMRC has been developing an outcomes evalua-
tion model for several years. The Council explains 
the rationale and objectives of the model thus: 
Scrutiny of the returns from the investment in re-
search is one of the consequences of the intro-
duction of an outcome-based accrual budgeting 
framework. The doubling of funding to the 
NHMRC, and the recommendations arising 
from the [Wills, 1998] Review, have encouraged 
the NHMRC to re-examine the way it performs 
its role as the peak funding body for Australian 
health and medical research … A key underlying 
theme of the Review calls for the NHMRC to 
develop an evaluation framework to quantify the 
outcomes of its investment in health and medical 
research … The Research Outcome Evaluation 
model … will form the basis of performance re-
porting for research funds managed by the 
NHMRC for the conduct of health and medical 
research. (NHMRC, 2001) 
In the course of preparing its 2000–2003 Perform-
ance Report (NHMRC, 2003a), NHMRC therefore 
sought to present data and case studies on the out-
puts, outcomes and impacts of its activities. The 
Council asked the current authors to review and re-
port upon performance indicators for HMRD that 
were in common use overseas (Turpin, Wixted and 
Garrett-Jones, 2003). The study had two main aims. 
1. Benchmarking HMRD performance The first ob-
jective was to compare the performance of Aus-
tralia’s HMRD with that of the HMRD sector in 
other selected countries. However, this seemingly 
simple question raises many issues about the ap-
propriate comparisons to attempt and the avail-
ability of data to support these comparisons. 
2. Benchmarking the use of performance indicators 
The second objective, therefore, was aimed at 
learning from international experience with 
HMRD performance indicators, particularly with 
regard to those used by medical research funding 
organisations with similar functions to NHMRC. 
Here the review examined the state of develop-
ment of international indicator systems for assess-
ing HMRD, and considered how Australia’s 
HMRD system in general and the NHMRC in par-
ticular compared with international practice in 
terms of the performance measurement frame-
works being used. 
The current paper briefly presents the main lessons 
learned from this study in the broader context of 
evaluation of HMRD. It explores, through examples, 
the feasibility of international benchmarking of 
HMRD and suggests how performance evaluation of 
HMRD in Australia could be further developed. 
Benchmarking of HMRD 
‘Benchmarking’ can encompass many types of com-
parison of performance (Bureau of Industry Eco-
nomics, 1996), but frequently implies a quantitative 
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comparison. Benchmarking may be carried out for 
the purpose of research evaluation, but has wider 
application in policy analysis — e.g. for comparing 
inputs or investments. 
Research evaluation is concerned, literally, with 
assessing the value of the work of a particular re-
searcher or research group, department, institution, 
agency or program. The focus is on the results, effi-
ciency and effectiveness of the activity rather than 
simply on its cost or use of resources. The aim of 
research evaluation is to demonstrate to a particular 
audience the appropriate performance of the activity 
in question — Irwin Feller uses the term ‘multiple 
publics’ in this context (Feller, 2002). This implies a 
requirement to tailor the performance measure to 
that audience and to use the sorts of evidence that 
the audience finds convincing (Garrett-Jones, 2000). 
A research council like NHMRC occupies a crucial 
‘middle level’ (between government central agencies 
like DoFA and the researchers) in assessing the per-
formance of research. In developing and using per-
formance indicators, it has to talk to both the 
sponsor and the performer of research in language 
that they understand, using measures of performance 
that they find convincing. These measures may be 
purely qualitative, and thus not amenable to 
‘benchmarking’. In summary, research evaluation 
and benchmarking are concepts that intersect but 
which are not identical. 
How do we apply them to evaluating HMRD? 
First, let us look at the components the HMRD sys-
tem and consider how elements of the system might 
be used to ‘benchmark’ performance between coun-
tries. Figure 1 presents a stylised model of a research 
system that might be applied to HMRD. 
Resources (recurrent funding, capital stock, per-
sonnel, existing knowledge, etc.) are the inputs to 
institutions or programs (research institutes, hospi-
tals, universities, research councils) which ‘convert’ 
them into research outputs (publications, research 
trained people, patents, etc). The outputs produce 
beneficial health or other socio-economic outcomes 
or impacts. The challenge for research evaluation is 
to be able to tie the outcomes/impacts sufficiently to 
the structures and institutions to be able to identify 
the better performing institutions, programs or ac-
tivities. These findings may influence the allocation 
of resources through some kind of feedback 
mechanism. In Australia, the federal education 
department’s funding formula for universities which 
takes account of various research ‘outputs’ is one 
example. 
One form of research benchmarking is the qualita-
tive international comparison often made by high-
level peer review panels. Here, the performance of a 
research discipline or institution may be ranked sub-
jectively on the basis of its perceived international 
standing in adequacy of resources, effectiveness of 
structures and quality of outputs and outcomes. In 
the USA, NIH and the Food and Drug Administra-
tion have been involved in international comparisons 
by expert panels of the status of emerging areas such 
as tissue engineering. In Australia, one can point to 
the Australian Research Council’s reviews of grant 
outcomes — for example, in molecular biology — 
and the review of the Australian National Univer-
sity’s Institute of Advanced Studies (which includes 
the John Curtin School of Medical Research) as in-
stances of qualitative benchmarking (ARC, 1994; 
1996). 
Defining the HMRD system 
The first issue is exactly how to define the scope of 
HMRD, as represented by the central box in Figure 
1. In practice it is quite difficult to come up with an 
acceptable definition for the ‘structures’ box in Fig-
ure 1. The OECD uses the term ‘non-market R&D’ 
to cover the public sector and non-profit private 
(PNP) foundations, but to exclude commercial 
HMRD performers. Alternatively, comparisons may 
be based upon government budget data (again as the 
OECD does) or funding, or on expenditures by par-
ticular agencies. 
Table 1 shows the broad picture of HMRD ex-
penditure and funding in Australia. From the table it 
is apparent that any analysis that considered only the 
Commonwealth government budget or the ‘non-
market’ sector, for example, would only partially 
cover the HMRD sector. An alternative approach is 
to try and compare specific sub-sectors or agencies 
— for example, health research councils in different 
countries, or various schemes for supporting col-
laborative research. 
In summary, the first problem in benchmarking is 
that structures, institutions and organisations are 
specific to the sector or country in question. Their 





















Figure 1. A stylised model of a research system for evaluation purposes, 
(after Arnold and Guy, 1998) 
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these measurements cannot be directly compared 
with the situation in other sectors or countries. 
Classifying the purpose of HMRD 
One way to overcome the constraint imposed by 
specific local structures and institutions is to adopt a 
functional classification for R&D carried out in all 
sectors (i.e. businesses, public institutes, universi-
ties, hospitals). This would allow, as an example, a 
comparison of R&D effort on reproductive medicine 
between countries. The federal statistics agency in 
Australia classifies all R&D by socio-economic  
objective (SEO). The SEO subdivision for ‘health’ 
covers ‘R&D directed towards human health, includ-
ing the understanding and treatment of clinical dis-
eases and conditions and the provision of public 
health and associated support services’ (Australian 
Bureau of Statistics, 1998). The subdivision has 
three groups: clinical (organs, diseases and abnormal 
conditions), public health, and health and support 
services. Comprising these groups are 49 classes, 
some of which refer to specific diseases or medical 
specialisms (e.g. endocrine organs and diseases 
(incl. diabetes); health related to ageing; diagnostic 
methods). R&D related to human pharmaceutical 
products and medical instrumentation are covered 
separately within the manufacturing subdivision of 
the classification. 
Australia is fortunate in the degree of detail pro-
vided in its functional (SEO) classification of R&D. 
Regrettably, such comprehensive SEO classifica-
tions are not widely used. As Alison Young (2001) 
comments: 
National specificities are particularly evident in 
the arrangements for non-market health R&D. 
National experts can mix and match institu-
tional and functional data to reach a data set 
that they feel gives a reasonable picture of the 
level and structure of the R&D activities of 
their own National Health Science and Innova-
tion Systems. Only Australia took a purely 
functional approach, providing series based on 
socio-economic objective and on field of S&T. 
Austria, Denmark, and to some extent Israel, 
also collected some project-level data in the 
non-market sector. Such detail was not avail-
able for Canada, France, the United Kingdom 
and the United States, which used semi-
institutional approaches. R&D in the medical 
sciences was included for the university sector 
Table 1. Australian HMRD expenditure by sector of funding and sector of performance, 2000 (A$ mill.) 
Sector providing funds Sector carrying out R&D 
 Government 
research institutes 







Commonwealth govt research 
agencies’ own funds 
 
21.3 
    
21.3 




    
51.9 
Universities’ own funding  
(general university funds)  
  
360.4 
   
360.4 
Business enterprises’ own 
funds 




Other Australian own funds   60.6  60.6 
Commonwealth govt funding  27.7 130.5 44.8  203.1 
Other Commonwealth govt 
funding for universities 
  
39.6 
   
39.6 




   
6.8 
State govt funding  18.9 27.8 20.6  67.4 
Universities’ funding  4.0  2.1  6.1 
Business funding 27.6 37.9 14.2  79.7 
Joint business/ govt funding  0.2  0.7  0.9 










Overseas funding  5.6 26.1 13.6  45.3 
Total HMRD 182.7 667.7 180.8 198.6 1,229.7 
Source: Turpin, Wixted and Garrett-Jones, 2003 
 
The performance of structures, 
institutions and organisations can be 
measured in many cases, but these 
measurements cannot be directly 
compared with the situation in other 
sectors or countries 
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(incl. university hospitals). France and the 
United States also included some (United 
States) or all (France) other life sciences. [Em-
phasis added] 
The second problem, then, is the lack of an interna-
tionally accepted, detailed functional classification 
of R&D. This seriously limits the scope for interna-
tional benchmarking of HMRD although, for the 
academic sector and for research publications, use of 
classification by field of research is an alternative 
approach. Analyses of the published outputs of Aus-
tralian HMRD (Butler, 2003) use three separate 
‘field’ classifications, for example.1 This situation is 
likely to improve. Through the Health Research Sys-
tems project the World Health Organisation (WHO) 
has supported work aimed at describing and measur-
ing health research systems in developing countries 
(Alano and Almario, 2000). The NHMRC is partici-
pating in the WHO project. 
Measuring inputs, outputs and outcomes 
Inputs and outputs can be counted more readily than 
outcomes and impacts. Research inputs (personnel 
and funding) are usually quantifiable. For most in-
puts the indicators are internationally standardised; 
for example, through adherence to the OECD’s 
‘Frascati family’ of guidelines and manuals. Interna-
tional standards or practices also exist for the meas-
urement of many research outputs (publications, 
qualified people, patents), through firms like the In-
stitute for Scientific Information (ISI) or agencies 
like national or regional patent offices. Outcomes 
and impacts, on the other hand, often cannot be sen-
sibly quantified and their assessment rests on quali-
tative criteria. A notable exception is the widespread 
use of impact measures of HMRD publications 
through analysis of the frequency of citations to pa-
pers in the international literature. International 
comparison is facilitated by ISI’s databases and 
common classifications of research fields. It can be 
argued that bibliometrics provides evidence of the 
scientific impact of research rather than of its contri-
bution to health outcomes. Given the time lag and 
the often indirect contribution of HMRD, attributing 
particular health outcomes to particular research 
programs is likely to be infeasible in most cases. 
Table 2 takes a real-life example and describes 
some of the indicators used to assess the perform-
ance of the Australian Cooperative Research Centres 
(CRCs). The program provides substantial funding 
for health and medical CRCs (Garrett-Jones and 
Turpin, 2002). These indicators are grouped under 
the headings of inputs, structures, outputs and out-
comes. As can be seen, the outcomes indicators rely 
heavily on qualitative assessments or case studies, 
although separate bibliometric analyses have looked 
at the relative impact of publications from the health 
and medical CRCs (Butler, 2003). The outcomes 
performance measures used by NHMRC also rely on 
a mix of qualitative information (such as ‘success 
stories’) and bibliometrics (NHMRC, 2002; 2003a). 
The NHMRC has made extensive use of bibliomet-
ric analyses in benchmarking Australian biomedical 
research and to determine the scientific impact of the 
work that the council itself funds (Butler, 2003; But-
ler and Biglia, 2001; Butler et al, 1998). Bibliomet-
ric evidence was used very effectively in the Wills 
Review of health research in Australia (Wills, 1999). 
The third problem, then, is the difficulty of com-
paring research outcomes between agencies, sectors 
or countries. Benchmarking of HMRD is therefore 
fraught with more uncertainty than are comparisons 
of ‘hard’ health infrastructure (e.g. hospital beds per 
1,000 population in different countries). Because we 
can measure them readily, it is more feasible to 
benchmark R&D inputs and outputs than it is to 
benchmark outcomes. But there remain substantial 
difficulties even in comparing the resources avail-
able to health research in different countries. 
International approaches 
Faced with these difficulties, what are other countries 
doing in HMRD evaluation methodology and prac-
tice? A selection of HMRD funding and research 
agencies from various countries (Table 3) is used to 
illustrate some differences and commonalities in the 
Table 2. Some performance indicators used for health and medical cooperative research centres in Australia 
Inputs Structures Outputs Outcomes 
Research staff 
Technical and support staff 
Research student enrolments 
Resources (staff, students, 
funding) by SEO and by sub-
program  
Cost per staff member 
Industry participation (no. of  
firms, funds) 
No. of students co-supervised by 
industry 
No. of participants in CRC (core/ 
supporting/other)  
Level and growth in funds and 
contributions from participants  
Proportion of levered funds to 
CRC program funds 
No. of strategic international 
alliances 
Contracted research and 
consulting (cases and income) 
Technology agreements, spin  
off companies 
Patents held and filed in  
Australia and overseas 
Technology transfer and 
professional training courses  
held (no. and income) 
Research student completions 
Qualitative statement of 
achievements and outcomes 
Defined successful outcomes in 
research, teaching and 
commercialisation 
Return on investment case studies
Qualitative account of most 
successful research outcomes 
No. of students taking up 
employment with industry 
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current use and development of performance indica-
tors. It appears that international HMRD agencies 
are under the same pressures as NHMRC to report 
on the outcomes of the research and training activi-
ties they carry out or fund. Thus, many are imple-
menting formal reporting of research ‘results’, 
usually through both statistical and qualitative 
measures of performance. Agencies faced with this 
task have adopted closely similar hierarchical ap-
proaches that 
•  identify the top level objectives that are to be 
achieved; 
•  show how the objectives of the research groups, 
centres, projects or institutions relate to the top 
level objectives; and 
•  specify available or potential indicators that can 
measure performance against both top level and 
research group objectives. 
About half of the agencies reviewed in Table 3 either 
publish such performance indicators, or are develop-
ing or planning to develop them. 
The review of the international data revealed sev-
eral common features in the evaluation systems used 
by HMRD agencies. 
•  Because of the relatively recent history of HMRD 
performance evaluation there is less international 
standardisation than in other sectors of research. 
However, the study found no fundamental differ-
ence between systems that aim to measure the per-
formance of HMRD and those for assessing 
research aimed at other socio-economic objectives. 
•  HMRD evaluation systems commonly take a hier-
archical approach, linking top level (government 
or agency) objectives to outcomes that are valued 
at the research level, and to specific indicators 
that can inform the assessment of these objectives 
and outcomes. 
•  The better performance measures systems  
integrate qualitative and quantitative measures of 
performance and internal and external assess-
ment. A framework that relies primarily on exter-
nal qualitative review is expensive and difficult to 
implement and the results are likely to be incom-
parable with those obtained by other agencies. 
Systems that rely on readily available, internally 
generated statistical data are easier to define and 
implement, but risk overlooking the assessment of 
quality and relevance that can be provided by ex-
ternal review. 
•  The long-term social impacts and health impacts 
of HMRD are commonly assessed through quali-
tative studies involving the potential beneficiaries 
rather than through standardised statistical indica-
tors. 
Benchmarking Australian HMRD 
While many agencies have or are developing sophis-
ticated performance measures, the issues outlined 
earlier mean that there is relatively sparse data avail-
Table 3. Use of performance indicators by HMRD agencies internationally
Country Health and medical R&D agency Status of performance indicators 
Canada Canadian Institutes of Health Research (CIHR),  
formerly the Medical Research Council (MRC) of 
Canada 
Reasonable information available. Performance 
indicators being further developed 
France Institut national de la sante et de la recherché medicale 
(INSERM) 
Limited information available on performance 
Germany Bundesministerium für Bildung und Forschung (BMBF) 
– the Federal Ministry of Education and Research 
Good information on the structure of the health and 
medical R&D system but availability of performance 
indicators limited 
The Netherlands Netherlands Organisation for Health R&D (Zon-Mw), 
incorporating the former Zorg-Onderzoek Nederland 
(ZON) – Health R&D Council and Medische 
Wetenschappen van NWO (MW-NOW) – Medical 
Sciences-Netherlands Organisation for Scientific 
Research 
Does not collect information on publications, patents or 
commercialisation activities 
New Zealand Health Research Council (HRC) Annual ‘Progress and Achievements Report’ gives 
qualitative and quantitative performance indicators. 
Funding a bibliometrics study of publications arising 
from HRC grants 
Singapore National Medical Research Council (NMRC), Ministry  
of Health 
Little relevant information found. Current output reported 
does not allow for useful comparisons with Australia 
South Africa Medical Research Council (MRC) Designing a performance indicators system 
Switzerland Swiss National Science Foundation (SNSF) Financial (research expenditure information only). 
Annual report does not report on performance 
indicators and other publications do not appear to 
carry such material 
United Kingdom Medical Research Council (MRC) Readily accessible information on performance. 
Performance indicators being further developed 
United States of America National Institutes of Health (NIH) Several sources of information including annual 
performance plans and reports. Performance 
indicators being further developed.   
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available for international benchmarking of HMRD. 
Some examples of feasible comparisons are given 
below. Each benchmark comprises a set of defined 
indicators (based on inputs, outputs and less com-
monly outcomes). As noted, the available compari-
sons are predominantly of research inputs and 
outputs, rather than outcomes. Comparisons are 
found within the following ‘domains’ or levels of 
evaluation: international, national, program or 
agency benchmarks. 
Intensity of HMRD spending 
Table 4 compares the intensity of national HMRD as 
a proportion of the national expenditure on health 
care in Australia and 10 other countries. The data are 
based on government budget expenditure for the 
main public HMRD agencies. As noted earlier, 
‘budget’ data are incomplete as a national picture, 
but as health care expenditure is also budget-driven, 
the comparison may be appropriate. Some estima-
tion is required, as in the alternative figures for 
Germany. HMRD spending per capita is given for 
comparison. 
The analysis reveals strong similarities between 
the countries (except the USA), with most spending 
between 0.3% and 0.55% of their health care budget 
on HMRD. Australia falls within the mid range of 
the countries examined. 
Functional priorities in HMRD 
Despite the problems of incompatible functional 
classifications of HMRD, the study attempted a 
breakdown by health objective for the major re-
search funding agencies in seven of the countries. 
Table 5 gives an (incomplete) indication of the re-
search priorities adopted by HMRD agencies in 
these countries. Agencies in several countries spent 
a similar proportion of their funding on AIDS re-
search, and the same pattern was true for the catego-
ries of mental health and infection/immunity. The 
table gives an idea of the value of benchmarking 
using a detailed classification of the objective of 
HMRD. Another way of examining the relative na-
tional priorities in HMRD, at least for the more fun-
damental research, is through a country’s share of 
world publications in a field (see Table 6). 
HMRD priorities in relation to burden of disease 
The federal and state governments in Australia have 
nominated seven national health priority areas based 
upon considerations of burden of disease and poten-
tial for improved health outcomes. These are: 
asthma, cancer control, cardiovascular health, diabe-
tes mellitus, injury prevention and control, mental 
health, and arthritis and musculoskeletal conditions 
Table 4. HMRD ‘budget’ funding as a proportion of national 
health care expenditure and per head 
Country HMRD as % of health 
care expenditure 
Institutional HMRD
funding per capita 
(US$) 
USA 1.50 64.06 
Singapore 1.24 8.14 
New Zealand 0.54 6.40 
UK 0.53 8.92 
Canada 0.41 8.02 
France 0.39 8.82 
Australia 0.38 6.89 
Netherlands 0.35 7.53 
Germany (Est. b) 0.31 8.43 
South Africa 0.31 0.70 
Switzerland 0.30 11.33 
Germany (Est. a) 0.20 5.50 
Source: Turpin, Wixted and Garrett-Jones, 2003 

















Cancer, cancer prevention and related disorders 14.9 5.4    21.0  
Cardiovascular health and diseases  11.0 3.7    8.7  
Endocrine diseases and diabetes  4.2       
Injury  3.2  3.6     
Mental health and neurosciences  16.0 13.2 15.3  16.7 25.3  
Respiratory diseases  4.9       
Bone, joint and muscle diseases  4.0       
Human genetics and inherited disorders  3.8 14.2 17.1     
Infection and immunity  16.4 13.4   16.7   
Liver, kidney and gastro-intestinal health and 
diseases  
4.9       
Other health issues, diseases and conditions  10.8       
Reproductive health  4.3       
Social and environmental health issues  1.6 1.2      
Population groups and health  0.8 6.0  14.0   
Health sector/system management  3.9 6.2     
AIDS research    10.7  10.7 10.7 
Source: Turpin, Wixted and Garrett-Jones, 2003 
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(Mathers et al, 1999). In 2003, over 60% of 
NHMRC funding was dedicated to research in these 
priority areas (NHMRC, 2003a). 
Research priorities within NHMRC have reflected 
national health priorities and, more recently, the na-
tional research priorities (NRPs). ‘Promoting and 
maintaining good health’ is one of four NRPs an-
nounced in 2002. Four specific goals — infant and 
child health, ageing, preventive healthcare, and the 
social and economic aspects of health — are identi-
fied as contributing to this priority. Research into 
biotechnology and genomics is included under other 
priority areas. 
In response to the NRP initiative, NHMRC estab-
lished strategic research networks (SRNs) in each of 
three health-related areas: ‘Healthy Start to Life’, 
‘Ageing Well, Ageing Productively’ and ‘Preventive 
Healthcare’. The Council has borrowed the concept  
of ‘consensus conferences’ from the US NIH with  
a view to developing further SRNs (NHMRC, 
2003b). The Council has also identified priority areas, 
most notably Aboriginal and Torres Strait Islander 
health. 
Unfortunately, the ability to benchmark these in-
vestments is severely limited by the lack of a com-
mon international functional or ‘disease-based’ 
classification for HMRD expenditures. 
HMRD outputs and impacts 
Ideally, the ‘priorities’ data in Table 5 (which meas-
ures funding inputs) should be compared with the 
performance of each field as measured by outputs, 
such as publications or patents, or impacts such as 
citations to Australian HMRD papers. Table 7 shows 
Australia’s ranking in published scientific papers in 
three HMRD sub-fields (clinical medicine, biomedi-
cal research, and health R&D) as defined by the US 
NSF. The countries chosen for comparison were the 
principal European OECD countries with Canada, 
the USA and New Zealand. Data are expressed as 
number of publications per head of population. Aus-
tralia ranks in the middle of the pack for both clini-
cal medicine and biomedical research. However, for 
its population size Australia publishes more research 
in the sub-field of ‘health’. The four Scandinavian 
countries are prominent towards the top of the list 
for both clinical and biomedical research. 
Data on publications can also be used as a measure 
of research impact. Using journals listed by the ISI for 
the period 1996–2000, Butler (2003) has investigated 
the citations attracted by published Australian bio-
medical papers against two benchmarks. The first 
compares the actual rate of citation to Australian  
Table 6. Australian and world citation rates for biomedical papers, 1996–2000
Research fielda Australia – 
no. of 
papers 
























Biological Sciences         





50,037  7.4  7.3  8.3 1.01  0.89  2.4% 
 Genetics 2,100  15,255  7.3  7.4  8.2 0.98  0.89  3.5% 
 Microbiology 1,668  8,542  5.1  5.0  5.0 1.02  1.02  2.8% 
 Biotechnology 2,147  10,058  4.7  4.6  4.6 1.02  1.03  2.6% 
Medical and health 
sciences 30,663  143,234  4.7  4.5  4.8 1.04  0.98  2.8% 
 Immunology 2,696  20,806  7.7  7.3  6.8 1.06  1.13  2.9% 
 Pharmacology and 
pharmaceutical science 2,654  10,028  3.8  4.1  4.0 0.92  0.95  2.1% 
 Medical physiology 2,253  7,731  3.4  3.6  3.9 0.95  0.89  4.1% 
 Neurosciences 3,048  16,553  5.4  5.9  6.3 0.93  0.87  2.4% 
 Clinical sciences 19,547  93,902  4.8  4.5  4.7 1.06  1.03  2.7% 
 Public health and health 
servicesc 3,412  10,235  3.0  3.0  3.3 1.00  0.90  3.7% 
 Medicine – general and 
internal 2,215  12,754  5.8  5.2  5.7 1.12  1.01  3.1% 
Multidisciplinary 
science 1,389  16,748  12.1  13.3  11.4 0.91  1.06  1.8% 
Source:  Data from Butler (2003) 
Notes:  a. Fields omitted because of low publication counts are: clinical chemistry; dentistry; nursing; human movement and sports  
science; and other medical and health sciences. 
 b. This measure is equivalent to the relative citation impact (RCI) indicator described by Butler et al, 1998. 
 c. ISI captures only about 25% of Australian articles in Public Health and health services. In other fields, ISI captures more than 
80% of articles. 
 
Another way of examining the relative 
national priorities in HMRD, at least 
for the more fundamental research, is 
through a country’s share of world 
publications in a field 
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papers to the average citation rate for papers in the 
journals in which they are published (the ‘expected’ 
citation rate). The second, the relative citation impact, 
or RCI (Butler et al, 1998), makes comparison with 
the world average for citations to biomedical papers 
published in all ISI-listed biomedical journals. These 
two benchmarks may differ if, for example, the Aus-
tralian papers are published in ‘lower impact’ jour-
nals, i.e. those with a lower average citation rate per 
paper, than is normal for the field. 
Table 7 shows the results of this comparison  
for selected main fields of HMRD. Butler (2003) 
demonstrates that, for most sub-fields in Australia, 
the actual citation rate per paper approaches or ex-
ceeds the ‘expected’ citation rate. The sub-fields of 
general medicine, immunology and clinical sciences 
show the highest citation impact. Using the RCI, the 
fields showing an impact greater than the world av-
erage are immunology, clinical sciences, biotechnol-
ogy and microbiology. Sub-fields like neuroscience 
and medical physiology return a relatively weaker 
performance against both indicators. 
Overall, Butler’s data (Table 6) suggest that the 
average citation rate of Australian biomedical papers 
is on a par with the international benchmarks, but 
there is a slight tendency for papers to appear in 
journals with a citation ‘impact’ that is lower than 
the world average. This suggests that fundamental 
HMRD is performing notably well by international 
benchmarks, but perhaps that Australia’s HMRD 
system overall is skewed towards applied research 
(which tends to be less highly cited), at least by 
comparison with the publications emanating from 
the major European and North American research 
centres which largely determine the ‘world’ average. 
While the data on publications and citations re-
veal that Australian HMRD has been performing 
strongly, the same does not appear true in patenting. 
A recent study of patenting in health-related fields 
(Lichtenberg and Virabhak, 2002) investigated pat-
enting in the field ‘Medical or Veterinary Science; 
Hygiene’ — meaning pharmaceuticals. The authors 
used the OECD ‘Triadic Patent Families’ database, 
which consolidates raw patent data from the Euro-
pean, Japanese and US Patent Offices. Among the 
benchmark OECD countries only New Zealand 
ranked lower than Australia in terms of its share of 
world health patents (Table 8). Furthermore, time 
series data show that Australia’s performance in pat-
enting, as a proportion of world activity, is declining 
(Lichtenberg and Virabhak, 2002). 
HMRD outputs benchmarked  
One of the concerns that prompted the current study 
was whether research funded by NHMRC was 
achieving appropriate outputs and outcomes by com-
parison with R&D funded by other research councils. 
Butler (2003) clearly demonstrates that research sup-
ported by the NHMRC attracted citation rates that 
were greater than the Australian average and, in all 
but two sub-fields, were also above the world average 
(i.e. RCI > 1.0). The rate of both actual and expected 
citations was substantially higher for the more fun-
damental research supported by the NHMRC or car-
ried out in specialist research institutes and 
cooperative research centres than for the biomedical 
publications from other research groups in govern-
ment laboratories, hospitals or universities. As there 
are few cases where HMRD activities can be com-
pared directly with similar international activities  
in other fields of research, Table 9 examines the  
Table 7. Ranked comparison of published papers in HMRD fields (papers/million pop. 1999)
Clinical medicine Biomedical R&D Health R&D All fields of research 
Sweden 383.5 Switzerland 162.5 Australia 12.6 Switzerland 979 
Switzerland 343.6 Sweden 154.2 UK 11.3 Sweden 940 
Finland 328.1 Denmark 139.0 Finland 10.1 Finland 779 
Denmark 287.3 Finland 113.0 Canada 9.7 Denmark 776 
Netherlands 253.0 USA 101.8 Sweden 9.4 UK 667 
UK 226.9 Netherlands 101.0 USA 9.0 Australia 661 
Norway 202.0 Canada 100.7 Netherlands 7.3 Netherlands 660 
Austria 197.8 UK 96.1 New Zealand 6.9 Canada 646 
Australia 197.1 Australia 89.3 Norway 5.8 New Zealand 623 
USA 192.9 Belgium 76.2 Denmark 3.9 USA 599 
Canada 192.4 Norway 72.8 Switzerland 2.9 Norway 582 
New Zealand 162.7 France 70.1 Belgium 1.4 Belgium 479 
Belgium 160.5 Germany 67.7 Germany 0.9 France 455 
Germany 134.5 Austria 62.4 Austria 0.9 Germany 454 
France 126.0 New Zealand 51.7 France 0.5 Austria 442 
Sources: Turpin, Wixted and Garrett-Jones, 2000; after National Science Foundation, 2002; population data from OECD, 2002. 
 
Perhaps Australia’s HMRD system 
overall is skewed towards applied 
research, at least by comparison with 
the publications emanating from the 
major European and North American 
research centres 
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contribution of HMRD within the Australian Coop-
erative Research Centres Program. Health and medi-
cal research accounts for around 11% of the 
researchers within the CRC program. However, 
medical CRCs contribute a higher proportion of CRC 
outputs in several areas, notably in the numbers of 
patents and the value of technology agreements. 
In summary, the range of ‘benchmarks’ of Austra-
lia’s HMRD performance is limited, and several in-
volve ‘best estimates’ of other countries’ 
performance. One should be rather cautious about 
interpretation, especially as no measures of the qual-
ity or international recognition of Australian HMRD 
(beyond those of citation impact) are presented. 
However, on the data available, Australia’s HMRD 
community seems to perform well, typically being 
ranked with the medium-sized European countries, 
Canada and New Zealand. There is little to separate 
these countries in terms of public resources for 
HMRD and they have rather similar research priori-
ties. Australia ranks close to the UK and USA in 
published papers (per capita) in clinical medicine 
and biomedical R&D and ahead of both in health 
R&D. Australia also performs very well in terms of 
the impact of published HMRD. Where Australia 
appears less competitive is in the area of potential 
commercial outcomes of research. The number of 
Australian health patents is around half that of the 
Netherlands, for example — a country with a similar 
population — and our output appears to be declin-
ing. This may reflect the performance of the busi-
ness sector, which is not well captured in the 
benchmarks presented. 
Conclusions and future work 
The current study revealed something of a paradox 
about benchmarking the performance of Australian 
HMRD. On the one hand, even though performance 
evaluation of HMRD is a relatively new area, many 
international HMRD agencies have developed for-
mal frameworks for reporting research ‘results’, or 
are doing so. On the other hand, there is rather lim-
ited scope for benchmarking of performance be-
tween countries. The prevalence of quantitative 
reporting on the basis of local organisational struc-
tures and categories makes even comparison of 
HMRD inputs difficult. 
It is important to stress that, while there is of 
course potential for Australia to learn from the ex-
perience of other countries and other fields of re-
search of performance evaluation — such as recent 
critiques of the influence of the US GPRA (Feller, 
2002) — the lack of comparability is not because we 
are dragging our heels. Through NHMRC, Australia 
is keeping abreast of international best practice in 
HMRD performance evaluation. Further, with the 
comprehensive Australian Standard Research Classi-
fications (ASRC) Australian statisticians are leaders 
in measuring detailed R&D objectives which help 
greatly in benchmarking R&D outcomes across the 
public and business sectors. 
What, then, is required to improve the evaluation 
and international benchmarking of Australian 
HMRD? In conclusion, we put forward some pro-
posals, pose some questions, and suggest possible 
avenues for future work. 
A more structured approach 
Without constructing a Byzantine evaluation frame-
work, first consideration must be given to the objec-
tive of the benchmarking and the appropriate 
indicators to include. This reiterates our earlier 
Table 8:  Health patents by OECD country of inventor, all 
years (1988–1995) 
Country No. of health patents 
(weighted) 
% of world health 
patents 
USA 22,409.4 55.8% 
EU 10,810.1 26.9% 
Japan 4,292.2 10.7% 
Germany 3,030.5 7.5% 
France 2,301.1 5.7% 
UK 2,225.5 5.5% 
Sweden 1,024.3 2.6% 
Switzerland 759.5 1.9% 
Italy 716.6  1.8% 
Canada 684.2 1.7% 
Netherlands 448.2 1.1% 
Denmark 311.6 0.8% 
Belgium 243.0 0.6% 
Australia 224.3 0.6% 
Austria 212.5 0.5% 
Spain 124.2 0.3% 
Finland 121.6 0.3% 
Norway 97.5 0.2% 
Korea 80.3 0.2% 
Hungary 58.3 0.2% 
Ireland 57.0 0.1% 
New Zealand 31.4 0.1% 
OECD 39,558.6 98.4% 
Source: Lichtenberg and Virabhak, 2002 
Table 9.  Outputs from medical Cooperative Research 
Centres in Australia 
CRC program performance  
measure 
Contribution of medical 
CRCs to the program total 
(1991–92 to 2000–01  
except where indicated) 
Researchers (full-time equivalent) 10.6% 
Papers accepted for publication 11.0% 
Journal articles published, 2000–01 12.3% 
Patents maintained in Australia 38.0% 
Patents filed in Australia 31.9% 




Patents filed overseas, 2000–01 25.0% 




Value of R&D contracts and  
consultancies (at 2001 prices) 
 
12.6% 
No. of technology agreements 11.8% 
Value of technology agreements 27.9% 
Source: Garrett-Jones and Turpin, 2002 
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comment on tailoring the evidence to the audience, 
in order to satisfy the ‘multiple publics’ for research 
evaluation. Both statistical indicators and measures 
of quality have a role in this process. In reviewing 
international practice the study observed four levels 
or ‘domains’ of benchmarking, as follows. 
•  International benchmarking — data that attempt 
to reflect the performance at the national level 
(e.g. research funding, publications, citation 
analyses and commercialisation indicators, such 
as patents). Because of government reporting re-
quirements, the emphasis to date has been on pub-
licly funded R&D. There is a need to incorporate 
the HMRD activities of business and the non-
government sector to give a full national picture. 
•  National benchmarking — benchmarking differ-
ent national agencies (e.g. NHMRC and the CRC 
program) serves to assess their contribution to-
ward national priorities. Here, some commonality 
of performance indicators between agencies 
would assist benchmarking, provided they were 
consistent with agencies’ goals. 
•  Agency/institute benchmarking — performance 
measures in this category would include areas 
such as the administrative cost and efficiency of 
administering programs, as well as some aggre-
gate of the program benchmarks described below. 
•  Program benchmarking — NIH’s program level 
benchmarks using descriptive performance as-
sessments and independent expert reviews pro-
vides a good example of this approach. Agencies 
such as NHMRC might record, on a regular basis, 
systematic information on qualitative outcomes. 
For example, grant recipients could be asked, on 
an annual basis, to identify and describe: (a) their 
most significant research breakthrough and (b) 
their most significant health/medical outcome. 
Each of these ‘domains’ contributes to an appropri-
ately balanced portfolio of performance measures for 
a HMRD agency. 
Common classifications? 
As we have noted, one significant impediment to 
benchmarking is a lack of standardisation in the 
classifications used internationally for HMRD. This 
makes it hard to compare rigorously even inputs to 
HMRD between countries. Various different classi-
fications are used for university and business re-
search, and for inputs and outputs. Often, data are 
expressed in terms of a hybrid classification of or-
ganisational units, health specialisms and specific 
diseases or other health problems. The latter are 
more likely to be of interest in assessing the contri-
bution of HMRD to improved health outcomes and 
reducing the quantified burden of particular diseases 
(Mathers et al, 1999). But, when it comes to the 
benchmarking the outcomes of HMRD, comparable 
international data are almost non-existent. 
International benchmarking of HMRD perform-
ance would certainly be simpler and more robust if a 
common international and cross-sectoral (public/ 
academic/private) detailed classification of HMRD 
objectives (SEO), like the Australian one, were to be 
implemented. This is, however, unlikely to come 
about quickly and, even if it did, would take us only 
part of the way towards comparing HMRD out-
comes. The goal of these classifications is to specify 
the intended beneficiary of the research, and the 
categories used are not necessarily those which 
would be most helpful for tracking outcomes. 
The more fundamental issue remains that of 
assessing the impact or outcomes of HMRD in terms 
which make sense to the researchers and stake-
holders involved, and expressing these in ways 
which bear international comparison. Performance 
evaluation will always require a mix of statistical 
indicators and more qualitative, descriptive informa-
tion on and expert assessment of research accom-
plishments. It is very hard to ‘benchmark’ the latter, 
although it can sometimes be put in semi-
quantitative terms (e.g. proportion of research objec-
tives met or not met). Any assessment of the out-
comes of HMRD is a two-stage process. It involves 
identifying the desired health outcomes, and then 
endeavouring to assess the contribution of HMRD to 
achieving those outcomes. In other words, bench-
marking of HMRD performance is informed by, and 
in turn informs, the development of health outcomes 
goals and indicators. It must involve both the health 
and medical research community (who are the best 
judges of research quality) and the users and practi-
tioners (who are best qualified to assess the impact 
and application of the research findings). 
Perhaps, when proposing international bench-
marks for HMRD outcomes, a more targeted, col-
laborative approach is therefore required. Clearly, 
there are many specific health issues (areas like 
HIV/AIDS or mental health) where improved out-
comes are of vital concern to many countries. Inter-
national cooperation to define these specific areas 
and to track the contribution of HMRD to improved 
outcomes is one way forward which is likely to be 
acceptable to many countries. Success in this ap-
proach might prompt a closer alignment of the more 
general R&D classifications with categories used by 
the health outcomes evaluation community. 
In conclusion, we would argue that further effort 
in assessing the outcomes and impacts of HMRD in 
Australia should be more closely connected with 
work that aims to develop health outcome indicators 
and measures of the health-related quality of life. 
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Notes 
1. These are the ISI subject category for journals, the ABS re-
search field, courses and disciplines (RFCD) categories, and 
an internal NHMRC classification which more closely reflects 
clinical specialisms. 
References 
B P J Alano and E S Almario (2000), Tracking Country Resource 
Flows for Health Research and Development (R&D): A Com-
parative Report on Malaysia, the Philippines and Thailand with 
a Manual on Tracking Resource Flows for Health Research 
and Development (Adarna House/Center for Economic Policy 
Research, Manila). 
E Arnold and K Guy (1998), ‘Technology diffusion programmes 
and the challenge for evaluation’, OECD Conference on Policy 
Evaluation in Innovation and Technology: Towards Best Prac-
tices, June 1997, Paris (OECD). 
Australian Bureau of Statistics (1998), Australian Standard Re-
search Classification 1998: A Set of Classifications for R&D 
Projects (ABS, Canberra). 
Australian Research Council (1994), Reviews of Grants Outcomes 
No. 12: Molecular Biology 1987–1991 (AGPS, Canberra). 
Australian Research Council (1996), The Australian Council Re-
view of the Institute of Advanced Studies (AGPS, Canberra). 
Bureau of Industry Economics (Australia) (1996), Science Sys-
tem: International Benchmarking (AGPS, Canberra). 
L Butler (2003), NHMRC-Supported Research: The Impact of 
Journal Publication Output 1996–2000 (NHMRC, Canberra). 
L Butler and B Biglia (2001), Analysing the Journal Output of 
NHMRC Research Grant Schemes (NHMRC, Canberra). 
L Butler, B Biglia and P Bourke (1998), Australian Biomedical 
Research: Funding Acknowledgments and Performance 
(NHMRC/AusInfo, Canberra). 
Commonwealth Scientific and Industrial Research Organisation 
(2002), Annual Report 2001-2002 (CSIRO, Canberra). 
S E Cozzens (2000), ‘Assessing federally-supported academic 
research in the United States’, Research Evaluation, 9(1), 
pages 5–10. 
Department of Finance and Administration (Australia) (2000), The 
Outcomes and Outputs Framework Guidance Document  
 
(DoFA, Canberra). 
I Feller (2002), ‘The good, the indifferent, and the less than attrac-
tive: II’, Research Evaluation, 11(2), pages 95–99. 
S Garrett-Jones (2000), ‘International trends in evaluating univer-
sity research outcomes: what lessons for Australia?’, Re-
search Evaluation, 8(2), pages 115–124. 
S Garrett-Jones and T. Turpin (2002), Measuring the Outcomes 
of the CRC Program: A Framework — Final Report (Dept of 
Education, Science and Training, Canberra). 
F Lichtenberg and S Virabhak (2002), ‘Using patents data to map 
technical change in health-related areas’, OECD STI Working 
Papers, 2002/16 (OECD, Paris). 
C Mathers, T Vos and C Stevenson (1999), The Burden of Dis-
ease and Injury in Australia (Australian Institute of Health and 
Welfare, Canberra). 
National Health and Medical Research Council (Australia) (2001), 
Health and Medical Research Strategic Review: Implementa-
tion of the Government’s Response — Final Report, October 
2000 (NHMRC, Canberra). 
National Health and Medical Research Council (Australia) (2002), 
Investing in Australia’s Health (Focus Publishing, Edgecliff). 
National Health and Medical Research Council (Australia) 
(2003a), Performance Measurement Report 2000–2003: A 
Report on the Performance of the National Health and Medical 
Research Council 2000–2003 (NHMRC, Canberra). 
National Health and Medical Research Council (Australia) 
(2003b), The National Research Priorities: NHMRC Implemen-
tation Plan (NHMRC, Canberra). 
National Science Foundation (2002), Science and Engineering 
Indicators 2002 (NSB, Virginia). 
OECD (2002), National Accounts of OECD Countries (CD-ROM) 
(OECD, Paris). 
G Ordóñez-Matamoros (2003), ‘The US NIH performance as-
sessment approach’, in Turpin, Wixted and Garrett-Jones, 
pages 59–68. 
T Turpin, B Wixted and S Garrett-Jones (2003), International 
Performance Indicators for Medical Research: Final Report to 
NHMRC (Australian Expert Group in Industry Studies [AEGIS], 
University of Western Sydney). 
P Wills (chair) (1998), The Virtuous Cycle: Working Together for 
Health and Medical Research: Health and Medical Research 
Strategic Review (the ‘Wills Review’) (Australian Government, 
Canberra). 
A Young (2001), Compiling Health Performer-Reported Health 
GERD: Measuring Expenditure on Health-Related R&D 
(OECD, Paris). 
 
